Changes of Radiation Treatment Concept Based on
PSMA
biochemical recurrence
early salvage radiotherapy
positron emission tomography (PET)
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
02
2021
accepted:
03
05
2021
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
19
6
2021
Statut:
epublish
Résumé
Salvage radiotherapy (SRT) is the main potentially curative treatment option for prostate cancer patients with post-prostatectomy PSA progression. Improved diagnostics by positron emission tomography/computed tomography (PET/CT) can lead to adjustments in treatment procedures (e.g. target volume of radiotherapy, androgen deprivation therapy). We analyzed the impact of We retrospectively analyzed 76 patients with biochemical recurrence after radical prostatectomy in whom SRT was planned after Without considering the PET/CT, all 76 patients would have been assigned to RT, 60 (79%) to the bed of the prostate and seminal vesicles alone, and 16 (21%) also to the pelvic lymph nodes because of histopathologic risk factors. Uptake indicative for tumor recurrence in Using
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Salvage radiotherapy (SRT) is the main potentially curative treatment option for prostate cancer patients with post-prostatectomy PSA progression. Improved diagnostics by positron emission tomography/computed tomography (PET/CT) can lead to adjustments in treatment procedures (e.g. target volume of radiotherapy, androgen deprivation therapy). We analyzed the impact of
PATIENTS AND METHODS
METHODS
We retrospectively analyzed 76 patients with biochemical recurrence after radical prostatectomy in whom SRT was planned after
RESULTS
RESULTS
Without considering the PET/CT, all 76 patients would have been assigned to RT, 60 (79%) to the bed of the prostate and seminal vesicles alone, and 16 (21%) also to the pelvic lymph nodes because of histopathologic risk factors. Uptake indicative for tumor recurrence in
CONCLUSION
CONCLUSIONS
Using
Identifiants
pubmed: 34141618
doi: 10.3389/fonc.2021.665304
pmc: PMC8204009
doi:
Types de publication
Journal Article
Langues
eng
Pagination
665304Informations de copyright
Copyright © 2021 Bottke, Miksch, Thamm, Krohn, Bartkowiak, Beer, Bolenz, Beer, Prasad and Wiegel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Strahlenther Onkol. 2018 Jul;194(7):646-654
pubmed: 29572670
BJU Int. 2016 May;117(5):732-9
pubmed: 26683282
EJNMMI Res. 2012 Jun 06;2(1):23
pubmed: 22673157
BMC Cancer. 2019 Jan 7;19(1):18
pubmed: 30616601
Prostate. 2017 Jun;77(8):920-927
pubmed: 28317152
Eur Urol. 2014 Aug;66(2):243-50
pubmed: 24680359
J Clin Oncol. 2016 Oct 20;34(30):3648-3654
pubmed: 27528718
Clin Nucl Med. 2016 Jul;41(7):515-21
pubmed: 26975008
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):20-30
pubmed: 29032394
J Nucl Med. 2019 Jul;60(7):963-970
pubmed: 30552203
EJNMMI Res. 2016 Dec;6(1):78
pubmed: 27785766
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19
pubmed: 29905907
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2339-2347
pubmed: 32157427
J Nucl Med. 2018 Feb;59(2):230-237
pubmed: 29123013
J Nucl Med. 2018 Jul 5;60(2):234-240
pubmed: 29976697
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
BJU Int. 2017 Aug;120(2):197-203
pubmed: 27981732
Urology. 2019 Jul;129:165-171
pubmed: 30928607
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):34-41
pubmed: 26404016
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16
pubmed: 18963539
Prostate Cancer Prostatic Dis. 2019 May;22(2):344-349
pubmed: 30487644